Table 6.

Median values, with minimum and maximum in brackets, of plasma endocannabinoids (eCBs) in dogs with Food-responsive Enteropathy (FRE, n = 10), Antibiotic-responsive Enteropathy (ARE, n = 9), and Immunosuppressive-responsive enteropathy (IRE, n = 14).

eCBs	FRE	ARE	IRE*	P-value	CE (non-PLE)	CE (PLE)	P-value
2-AG	3.2 (1.9–22.2)	11.2 (3.3–31.5)	31.5 (3.9–220.6)	<0.001†	7.3 (1.9–169.9)	38.3 (9.0–222.6)	0.033
AEA	2.0 (1.0–4.1)	1.6 (1.0–4.8)	1.6 (0.9–2.7)	0.581	1.9 (0.9–4.8)	1.0 (0.9–2.5)	0.035
PEA	49.0 (29.3–120.3)	38.3 (22.5–47.6)	39.2 (8.0–85.1)	0.068	41.7 (8.8–120.3)	11.9 (8.0–55.4)	0.016
OEA	93.0 (32.8–167.0)	67.0 (33.8–103.6)	26.2 (2.8–102.8)	<0.01†	67.3 (17.2–167.0)	26.2 (2.8–49.8)	0.023

Median values, with minimum and maximum in brackets, of plasma endocannabinoids (eCBs) in dogs with chronic enteropathy with (PLE, n = 5) and without Protein Losing Enteropathy (non-PLE, n = 28). CE, Chronic Enteropathy; 2-AG, 2-arachidonoylglycerol; AEA, N-arachidonoylethanolamine; PEA, palmitoylethanolamide; OEA, oleoylethanolamide.

^*IRE group includes five PLE dogs.

^†significant difference between IRE and FRE dogs. Italic denotes significance.